Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2416 entries
Sorted by: Best Match Show Resources per page
Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis.

Translational oncology

Chen R, Peng PC, Wen B, Li FY, Xie S, Chen G, Lu J, Peng Z, Tang SB, Liang YM, Deng X.
PMID: 26947879
Transl Oncol. 2016 Feb;9(1):32-40. doi: 10.1016/j.tranon.2015.11.010.

This systematic review and meta-analysis evaluated anti-programmed cell death (PD)-1 immunotherapy (nivolumab or pembrolizumab) for overall efficacy, safety, and effective dose relative to standard chemotherapy or other conventional drugs in the treatment of malignant tumors. We searched the following...

Cite
Chen R, Peng PC, Wen B, et al. Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol. 2016;9(1):32-40doi: 10.1016/j.tranon.2015.11.010.
Chen, R., Peng, P. C., Wen, B., Li, F. Y., Xie, S., Chen, G., Lu, J., Peng, Z., Tang, S. B., Liang, Y. M., & Deng, X. (2016). Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Translational oncology, 9(1), 32-40. https://doi.org/10.1016/j.tranon.2015.11.010
Chen, Ran, et al. "Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis." Translational oncology vol. 9,1 (2016): 32-40. doi: https://doi.org/10.1016/j.tranon.2015.11.010
Chen R, Peng PC, Wen B, Li FY, Xie S, Chen G, Lu J, Peng Z, Tang SB, Liang YM, Deng X. Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol. 2016 Feb;9(1):32-40. doi: 10.1016/j.tranon.2015.11.010. PMID: 26947879; PMCID: PMC4800062.
Copy Download .nbib Format: NLM
The Role of NG2 Proteoglycan in Glioma.

Translational oncology

Yadavilli S, Hwang EI, Packer RJ, Nazarian J.
PMID: 26947882
Transl Oncol. 2016 Feb;9(1):57-63. doi: 10.1016/j.tranon.2015.12.005.

Neuron glia antigen-2 ((NG2), also known as chondroitin sulphate proteoglycan 4, or melanoma-associated chondroitin sulfate proteoglycan) is a type-1 membrane protein expressed by many central nervous system (CNS) cells during development and differentiation and plays a critical role in...

Cite
Yadavilli S, Hwang EI, Packer RJ, et al. The Role of NG2 Proteoglycan in Glioma. Transl Oncol. 2016;9(1):57-63doi: 10.1016/j.tranon.2015.12.005.
Yadavilli, S., Hwang, E. I., Packer, R. J., & Nazarian, J. (2016). The Role of NG2 Proteoglycan in Glioma. Translational oncology, 9(1), 57-63. https://doi.org/10.1016/j.tranon.2015.12.005
Yadavilli, Sridevi, et al. "The Role of NG2 Proteoglycan in Glioma." Translational oncology vol. 9,1 (2016): 57-63. doi: https://doi.org/10.1016/j.tranon.2015.12.005
Yadavilli S, Hwang EI, Packer RJ, Nazarian J. The Role of NG2 Proteoglycan in Glioma. Transl Oncol. 2016 Feb;9(1):57-63. doi: 10.1016/j.tranon.2015.12.005. PMID: 26947882; PMCID: PMC4800061.
Copy Download .nbib Format: NLM
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.

Translational oncology

Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H.
PMID: 26947883
Transl Oncol. 2016 Feb;9(1):64-69. doi: 10.1016/j.tranon.2016.01.003.

BACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1 (PD-L1) expression measured by immunohistochemistry may predict response to anti-programmed cell death 1 (PD-1) therapy. Results on the association between PD-L1 expression and survival among patients...

Cite
Sorensen SF, Zhou W, Dolled-Filhart M, et al. PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl Oncol. 2016;9(1):64-69doi: 10.1016/j.tranon.2016.01.003.
Sorensen, S. F., Zhou, W., Dolled-Filhart, M., Georgsen, J. B., Wang, Z., Emancipator, K., Wu, D., Busch-Sørensen, M., Meldgaard, P., & Hager, H. (2016). PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Translational oncology, 9(1), 64-69. https://doi.org/10.1016/j.tranon.2016.01.003
Sorensen, Steffen Filskov, et al. "PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy." Translational oncology vol. 9,1 (2016): 64-69. doi: https://doi.org/10.1016/j.tranon.2016.01.003
Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H. PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl Oncol. 2016 Feb;9(1):64-69. doi: 10.1016/j.tranon.2016.01.003. PMID: 26947883; PMCID: PMC4800057.
Copy Download .nbib Format: NLM
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.

Translational oncology

Robl B, Botter SM, Boro A, Meier D, Neri D, Fuchs B.
PMID: 28448958
Transl Oncol. 2017 Jun;10(3):419-430. doi: 10.1016/j.tranon.2017.02.005. Epub 2017 Apr 25.

The targeted delivery of tumor necrosis factor-α (TNF-α) with antibodies specific to splice isoforms of fibronectin [e.g., F8-TNF, specific to the extra-domain A (EDA) domain of fibronectin] has already shown efficacy against experimental sarcomas but has not yet been...

Cite
Robl B, Botter SM, Boro A, et al. Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma. Transl Oncol. 2017;10(3):419-430doi: 10.1016/j.tranon.2017.02.005.
Robl, B., Botter, S. M., Boro, A., Meier, D., Neri, D., & Fuchs, B. (2017). Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma. Translational oncology, 10(3), 419-430. https://doi.org/10.1016/j.tranon.2017.02.005
Robl, Bernhard, et al. "Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma." Translational oncology vol. 10,3 (2017): 419-430. doi: https://doi.org/10.1016/j.tranon.2017.02.005
Robl B, Botter SM, Boro A, Meier D, Neri D, Fuchs B. Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma. Transl Oncol. 2017 Jun;10(3):419-430. doi: 10.1016/j.tranon.2017.02.005. Epub 2017 Apr 25. PMID: 28448958; PMCID: PMC5406547.
Copy Download .nbib Format: NLM
Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis.

Translational oncology

Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H.
PMID: 28448960
Transl Oncol. 2017 Jun;10(3):442-449. doi: 10.1016/j.tranon.2017.02.009. Epub 2017 Apr 25.

Distinguishing synchronous and metachronous primary lung adenocarcinomas from adenocarcinomas with intrapulmonary metastasis is essential for optimal patient management. In this study, multiple lung adenocarcinomas occurring in the same patient were evaluated using comprehensive histopathologic evaluation supplemented with molecular analysis....

Cite
Saab J, Zia H, Mathew S, et al. Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis. Transl Oncol. 2017;10(3):442-449doi: 10.1016/j.tranon.2017.02.009.
Saab, J., Zia, H., Mathew, S., Kluk, M., Narula, N., & Fernandes, H. (2017). Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis. Translational oncology, 10(3), 442-449. https://doi.org/10.1016/j.tranon.2017.02.009
Saab, Jad, et al. "Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis." Translational oncology vol. 10,3 (2017): 442-449. doi: https://doi.org/10.1016/j.tranon.2017.02.009
Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H. Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis. Transl Oncol. 2017 Jun;10(3):442-449. doi: 10.1016/j.tranon.2017.02.009. Epub 2017 Apr 25. PMID: 28448960; PMCID: PMC5406583.
Copy Download .nbib Format: NLM
Proving of a Mathematical Model of Cell Calculation Based on Apparent Diffusion Coefficient.

Translational oncology

Surov A, Garnov N.
PMID: 28863287
Transl Oncol. 2017 Oct;10(5):828-830. doi: 10.1016/j.tranon.2017.08.001. Epub 2017 Aug 29.

OBJECTIVES: Recently, Atuegwu et al. proposed a mathematical model based on ADCMETHODS: For this study, we re-analyzed our previous data regarding associations between ADC parameters and histopathological findings. Overall, 134 patients with different tumors were acquired for the analysis....

Cite
Surov A, Garnov N. Proving of a Mathematical Model of Cell Calculation Based on Apparent Diffusion Coefficient. Transl Oncol. 2017;10(5):828-830doi: 10.1016/j.tranon.2017.08.001.
Surov, A., & Garnov, N. (2017). Proving of a Mathematical Model of Cell Calculation Based on Apparent Diffusion Coefficient. Translational oncology, 10(5), 828-830. https://doi.org/10.1016/j.tranon.2017.08.001
Surov, Alexey, and Garnov, Nikita. "Proving of a Mathematical Model of Cell Calculation Based on Apparent Diffusion Coefficient." Translational oncology vol. 10,5 (2017): 828-830. doi: https://doi.org/10.1016/j.tranon.2017.08.001
Surov A, Garnov N. Proving of a Mathematical Model of Cell Calculation Based on Apparent Diffusion Coefficient. Transl Oncol. 2017 Oct;10(5):828-830. doi: 10.1016/j.tranon.2017.08.001. Epub 2017 Aug 29. PMID: 28863287; PMCID: PMC5577394.
Copy Download .nbib Format: NLM
Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Translational oncology

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A.
PMID: 26310373
Transl Oncol. 2015 Aug;8(4):273-8. doi: 10.1016/j.tranon.2015.05.002.

Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism as a potential predictive factor of poor prognosis...

Cite
Divella R, Daniele A, Abbate I, et al. Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. Transl Oncol. 2015;8(4):273-8doi: 10.1016/j.tranon.2015.05.002.
Divella, R., Daniele, A., Abbate, I., Savino, E., Casamassima, P., Sciortino, G., Simone, G., Gadaleta-Caldarola, G., Fazio, V., Gadaleta, C. D., Sabbà, C., & Mazzocca, A. (2015). Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. Translational oncology, 8(4), 273-8. https://doi.org/10.1016/j.tranon.2015.05.002
Divella, Rosa, et al. "Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE." Translational oncology vol. 8,4 (2015): 273-8. doi: https://doi.org/10.1016/j.tranon.2015.05.002
Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A. Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. Transl Oncol. 2015 Aug;8(4):273-8. doi: 10.1016/j.tranon.2015.05.002. PMID: 26310373; PMCID: PMC4562977.
Copy Download .nbib Format: NLM
Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer.

Translational oncology

Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO.
PMID: 26310375
Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001.

BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cancer cells. Hypermethylation of the promoter represses expression of the IGFBP-3 gene. We undertook this study to assess the impact of IGFBP-3 methylation on survival of...

Cite
Kim ST, Jang HL, Lee J, et al. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Transl Oncol. 2015;8(4):288-94doi: 10.1016/j.tranon.2015.06.001.
Kim, S. T., Jang, H. L., Lee, J., Park, S. H., Park, Y. S., Lim, H. Y., Choi, M. G., Bae, J. M., Sohn, T. S., Noh, J. H., Kim, S., Kim, K. M., Kang, W. K., & Park, J. O. (2015). Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Translational oncology, 8(4), 288-94. https://doi.org/10.1016/j.tranon.2015.06.001
Kim, Seung Tae, et al. "Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer." Translational oncology vol. 8,4 (2015): 288-94. doi: https://doi.org/10.1016/j.tranon.2015.06.001
Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. PMID: 26310375; PMCID: PMC4562974.
Copy Download .nbib Format: NLM
Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.

Translational oncology

Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK.
PMID: 28342996
Transl Oncol. 2017 Jun;10(3):357-366. doi: 10.1016/j.tranon.2017.01.011. Epub 2017 Mar 24.

Prostate cancer (PCa) remains the second-leading cause of cancer-related deaths in American men with an estimated mortality of more than 26,000 in 2016 alone. Aggressive and metastatic tumors are treated with androgen deprivation therapies (ADT); however, the tumors acquire...

Cite
Yadav SS, Li J, Stockert JA, et al. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Transl Oncol. 2017;10(3):357-366doi: 10.1016/j.tranon.2017.01.011.
Yadav, S. S., Li, J., Stockert, J. A., Herzog, B., O'Connor, J., Garzon-Manco, L., Parsons, R., Tewari, A. K., & Yadav, K. K. (2017). Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Translational oncology, 10(3), 357-366. https://doi.org/10.1016/j.tranon.2017.01.011
Yadav, Shalini S, et al. "Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications." Translational oncology vol. 10,3 (2017): 357-366. doi: https://doi.org/10.1016/j.tranon.2017.01.011
Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Transl Oncol. 2017 Jun;10(3):357-366. doi: 10.1016/j.tranon.2017.01.011. Epub 2017 Mar 24. PMID: 28342996; PMCID: PMC5369368.
Copy Download .nbib Format: NLM
Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters.

Translational oncology

Surov A, Gottschling S, Mawrin C, Prell J, Spielmann RP, Wienke A, Fiedler E.
PMID: 26692534
Transl Oncol. 2015 Dec;8(6):517-23. doi: 10.1016/j.tranon.2015.11.012.

OBJECTIVES: To analyze diffusion-weighted imaging (DWI) findings of meningiomas and to compare them with tumor grade, cell count, and proliferation index and to test a possibility of use of apparent diffusion coefficient (ADC) to differentiate benign from atypical/malignant tumors.METHODS:...

Cite
Surov A, Gottschling S, Mawrin C, et al. Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. Transl Oncol. 2015;8(6):517-23doi: 10.1016/j.tranon.2015.11.012.
Surov, A., Gottschling, S., Mawrin, C., Prell, J., Spielmann, R. P., Wienke, A., & Fiedler, E. (2015). Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. Translational oncology, 8(6), 517-23. https://doi.org/10.1016/j.tranon.2015.11.012
Surov, Alexey, et al. "Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters." Translational oncology vol. 8,6 (2015): 517-23. doi: https://doi.org/10.1016/j.tranon.2015.11.012
Surov A, Gottschling S, Mawrin C, Prell J, Spielmann RP, Wienke A, Fiedler E. Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. Transl Oncol. 2015 Dec;8(6):517-23. doi: 10.1016/j.tranon.2015.11.012. PMID: 26692534; PMCID: PMC4700293.
Copy Download .nbib Format: NLM
Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation.

Translational oncology

Zhang F, Qu J, Zhang H, Liu H, Qin J, Ding Z, Li Y, Ma J, Zhang Z, Wang Z, Zhang J, Zhang S, Dong Y, Grimm R, Kamel IR, Li H.
PMID: 28327459
Transl Oncol. 2017 Jun;10(3):324-331. doi: 10.1016/j.tranon.2017.02.006. Epub 2017 Mar 19.

PURPOSE: To compare the T staging of potentially resectable esophageal cancer using free-breathing radial VIBE (r-VIBE) and breath-hold Cartesian VIBE (C-VIBE), with pathologic confirmation of the T stage.MATERIALS AND METHODS: Fifty patients with endoscopically proven esophageal cancer and indeterminate...

Cite
Zhang F, Qu J, Zhang H, et al. Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation. Transl Oncol. 2017;10(3):324-331doi: 10.1016/j.tranon.2017.02.006.
Zhang, F., Qu, J., Zhang, H., Liu, H., Qin, J., Ding, Z., Li, Y., Ma, J., Zhang, Z., Wang, Z., Zhang, J., Zhang, S., Dong, Y., Grimm, R., Kamel, I. R., & Li, H. (2017). Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation. Translational oncology, 10(3), 324-331. https://doi.org/10.1016/j.tranon.2017.02.006
Zhang, Fengguang, et al. "Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation." Translational oncology vol. 10,3 (2017): 324-331. doi: https://doi.org/10.1016/j.tranon.2017.02.006
Zhang F, Qu J, Zhang H, Liu H, Qin J, Ding Z, Li Y, Ma J, Zhang Z, Wang Z, Zhang J, Zhang S, Dong Y, Grimm R, Kamel IR, Li H. Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation. Transl Oncol. 2017 Jun;10(3):324-331. doi: 10.1016/j.tranon.2017.02.006. Epub 2017 Mar 19. PMID: 28327459; PMCID: PMC5358929.
Copy Download .nbib Format: NLM
Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome.

Translational oncology

Tertipis N, Haeggblom L, Grün N, Nordfors C, Näsman A, Dalianis T, Ramqvist T.
PMID: 25749172
Transl Oncol. 2015 Feb;8(1):10-7. doi: 10.1016/j.tranon.2014.11.002.

OBJECTIVES: Patients with human papillomavirus (HPV)-positive tonsillar squamous cell carcinoma (TSCC) and base of tongue squamous cell carcinoma (BOTSCC) have a better clinical outcome than those with corresponding HPV-negative tumors. Moreover, there is a strong positive correlation between absent/low...

Cite
Tertipis N, Haeggblom L, Grün N, et al. Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome. Transl Oncol. 2015;8(1):10-7doi: 10.1016/j.tranon.2014.11.002.
Tertipis, N., Haeggblom, L., Grün, N., Nordfors, C., Näsman, A., Dalianis, T., & Ramqvist, T. (2015). Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome. Translational oncology, 8(1), 10-7. https://doi.org/10.1016/j.tranon.2014.11.002
Tertipis, Nikolaos, et al. "Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome." Translational oncology vol. 8,1 (2015): 10-7. doi: https://doi.org/10.1016/j.tranon.2014.11.002
Tertipis N, Haeggblom L, Grün N, Nordfors C, Näsman A, Dalianis T, Ramqvist T. Reduced Expression of the Antigen Processing Machinery Components TAP2, LMP2, and LMP7 in Tonsillar and Base of Tongue Cancer and Implications for Clinical Outcome. Transl Oncol. 2015 Feb;8(1):10-7. doi: 10.1016/j.tranon.2014.11.002. PMID: 25749172; PMCID: PMC4350639.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2416 entries